

# First Look Awards FY25 Application

Applicant Name (Organization) (required)
Select v
This will automatically be blinded to reviewers.
Non-Profit Principal Investigator (required)
First Name Last Name
This will automatically be blinded to reviewers.
Title of Non-Profit Principal Investigator
This will automatically be blinded to reviewers.
Email of Non-Profit Principal Investigator (required)
email@example.com
This will automatically be blinded to reviewers.
Phone of Non-Profit Principal Investigator (required)
<b>=</b> \( \big  \)
This will automatically be blinded to reviewers.
Authorized Representative (required)
First Name (required)
Last Name (required)

This will automatically be blinded to reviewers.

	Form saved successfully.	
This will automatically be blinded to reviewers.	Torin saved successiony.	
Email of Authorized Representative (re	quired)	
email@example.com		
This will automatically be blinded to reviewers.		
Address of Non-Profit Entity (required)		
This will automatically be blinded to reviewers.		
City/Town of Non-Profit Entity		
Select		•
This will automatically be blinded to reviewers.		
Zip Code of Non-Profit Entity (required)		
Select		~
This will automatically be blinded to reviewers.		
Name of Press Contact (required)		
First Name (required)		
Last Name (required)		
This will automatically be blinded to reviewers.		
Email Address of Press Contact (require	·d)	
email@example.com		
This will automatically be blinded to reviewers.		
Press Contact Telephone (required)		
~		
This will automatically be blinded to reviewers.		

		ualifications of the team	, the MLSC will blind the
uired)			
eviewers.			
(ioquiios)			
ired)			
perience, without i	dentifying him/her I	oy name or gender	· (required)
			Limit: 500 words
	s or she/her/hers). Ex. The clinical trials. The PI is th		
			erience administering
			erience administering
	to reviewers during the uired)  eviewers.  tment (required)  ired)	to reviewers during the review process.  uired)  eviewers.  tment (required)  ired)	uired)  eviewers.  tment (required)

'	Co-Principal Investigator Co-PI) Name	Co-PI Title	e	Organizatio	n Name	Organization	on	Co-PI E-Mail Addres
2								
3								
4								
iewers	ve CO-PRINCIPAL INVEST s. nave co-PI(s), describ							
								Limit: 250 woi
niniste	on't use co-Pl's name or g ering and managing projec e in the areas of XYZ							
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	al to MLSC							
Propo	osal Title (required)							
n <b>at d</b> i	osal Title (required)  lisease(s) or condition d)  utoimune Disorders	n(s) does th		_	tudy? Pl		ose up	to three options.  Cancer - Ovarian
n <b>at d</b> i quirec Au Ca Ca	lisease(s) or conditio	_	Breast	Ca	-	ers	ose up	·
nat di quirec Au Ca Ca Res	lisease(s) or condition d) utoimune Disorders ardiology/ ardiovascular	Cancer -	Breast sease	Ca	nncer - Oth	ers	ose up	Cancer - Ovarian
nat di quirec Au Ca Ca Res	lisease(s) or condition d) utoimune Disorders ardiology/ ardiovascular esearch	Cancer - Chronic Illness/Di	Breast sease	Ca	ncer - Oth	ers	ose up	Cancer - Ovarian  Environmental Health  Immunology/Inflammat
nat di quirec Au Ca Ca Re: Ga	lisease(s) or condition (d)  utoimune Disorders  ardiology/ ardiovascular esearch  astrointestinal (GI)	Cancer - Chronic Illness/Di	Breast sease & ogy	Ca	nncer - Otho docrinolog	ers Jy int Health	ose up	Cancer - Ovarian  Environmental Health  Immunology/Inflammat ion

D

Е

С

В

	Rare Diseases		Regenerative Medicine Form saved	succe	Reproductive Health ssfully.		Toxicology
	Women's Health/ Gender Studies		Other		N/A		
	at modality/modalitie uired)	s doe	s your project primar	ily en	nploy? Please choose	e up t	o three options.
	Cell & Gene Therapy		Clinical Trials		Data Science		Diagnostics
	Digital Health		Drug Delivery		Drug Discovery & Development		Imaging
	Medical Device		mRNA/siRNA/ RNA Research		Personalized/Precision Medicine		Phototherapy
	Radiation Therapy		Robotics		Vaccines		Other
	N/A						
Wha	nt are tools and techr	niques	s used in your projec	t? Ple	ase choose up to thr	ee op	otions. (required)
	3D printing		AI/ML/Deep Learning		Antibody		Automation
	Biomanufacturing		Biomarker Identification		Biomaterials/ Material Sciences		Biosensor
	Contract Work- CRO/CDMO/CMO		Crystallography/ Peptide synthesis		CT/MRI		Data Optimization
	EEG&ECG		Electronic Medical Record (EMR)		Engineered Microbes		FACS/ Flow Cytometry
	Genome Editing		Genomics		In Vitro cultures		In Vivo animal models
	Liquid Chromatography		Mass Spectroscopy		Metabolomics		Microscopy
	Nanotechnology		Next-generation Sequencing		NMR/MRS		Organoid/ Organ-on-a- chip
	Pasteurization/ Sterilization		Patient Avatars		Proteomics		Small Molecule
	Software & Algorithms		Transcriptomics		Ultrasound		Viral Vector
	Other		N/A				

## CITATION LIST - end of the proposal section

If you reference research or statistics, please **provide a citation** to identify the source of the information. You will be given the option to input your references if you have used any, in the order they appear in the application at the end of this section (Question 12).

CITATIONS ARE OPTIONAL

	Form saved successfully.		
		Liı	mit: 250 word
3. Describe the clinical/scientific need	I or problem the project see	ks to address. (required)	
		Li	mit: 150 word
1. Describe the proposed solution. (red	quired)		
		Liı	mit: 300 word
5. What work has been done to this p	oint that supports the proje	ct outlined in the application	<b>1?</b> (required)
		Liı	nit: 250 word
6. Describe the potential impact and t	· · · · · · · · · · · · · · · · · · ·	vill have on women's health	and
gender biology moving forward. (requir	red)		
gender biology moving forward. (requir	red)		
gender biology moving forward. (requir	red)	Liı	,
7. What is the gender distribution betw	ween animals/cell lines to b	e studied and how will gend	nit: 250 word
gender biology moving forward. (required)  7. What is the gender distribution between the differences be reported? If gender will	ween animals/cell lines to b	e studied and how will gend	nit: 250 word

please explain why. (required)

D. What are the key challenges to successful translation of the technology and how do you plovercome them? (required)  Lin  O. Who are potential strategic partners and have you engaged in preliminary conversations?	mit: 250 words
vercome them? (required)  Lin  D. Who are potential strategic partners and have you engaged in preliminary conversations?	nit: 250 word
. Who are potential strategic partners and have you engaged in preliminary conversations?	
. Who are potential strategic partners and have you engaged in preliminary conversations?	
	(required)
Liı	
Liı	
	mit: 150 words
Liı <b>on't use PI's name</b> in this section.	mit: 150 word:
2. Enter citations in the order that they appear in your application. Please do NOT mention tlame.	he Pl's
	,
udget	

**Budget Form Instructions** 

A maximum of \$50,000 in expenses can be requested through this grant.

**Expenses** can include: equipment, research supplies and reagents (no minimum dollar amount), purchase of hardware and software, equipment maintenance contract and service contract costs, data generated via core facilities, salary support with **fringe rate not to exceed 30%**, legal and publication fees, consultants, and project-related travel (up to 10%). These funds may cover **indirect costs, up to 15%** (or \$6,522 for an award of \$50,000).

EXAMPLES of funding CATEGORIES are equipment, research supplies, reagents, hardware, software, data sets, salary support, indirect costs, consultant, legal fees, publication fees, travel. If you haven't decided on vendors for supplies, please list multiple ones.

, 7

For salary support and indirect costs use your organization's name in the Vendor column. **DO NOT MENTION THE PI/CO-PI BY NAME in the budget form.** 

#### Funding Budget Requested (required)

							<b>10</b> *
	Α	В	С	D	Е	F	C
1	FY25 Budget Details						
2	-	-	-				
3	Vendor	Item/ Description	Category (please choose from the list of	Amount (\$)	Upto - \$50000		List of Categor
4							equipme
5							research supplies
6							reagents
7							hardwar
8							software
4		•					<b>•</b>

! The "Funding Budget Requeste	ed" field is required.
--------------------------------	------------------------

#### **Signature**

### **Blinded Declaration**

The MLSC is making a concerted effort to blind applications from reviewers. As such we are requesting that you please do not mention the PI by name or gender unless specifically requested.

If there is mention of the Pl's name or gender in the submitted application, except where explicitly requested, **your application may be deemed ineligible.** Prior to submission, please use **CTRL+F** to search the application for the **Pl's name and gendered pronouns (he/him/his or she/her/hers)** in all text fields, references, and patents to ensure that they are only found in fields where specifically requested.

Once you are ready to submit, please agree to the declaration below by selecting the below checkbox.

□ ex	cept where explicitly asked. I understand that if the PI's name or gender in any text fields or uploads, we cept where explicitly asked. I understand that if the PI's name or gender remains in the plication, except where explicitly requested, my application may be ineligible.
Autho	rized Signature and Acceptance (required)
	Choose File
Upload	a file. No files have been attached yet.
Accepta	ble file types: .pdf, .jpg, .jpeg, .png
Please ι	upload an image of the signature.
Authoria	zed Representative Signature and Acceptance
above ir	hat I am authorized to commit my organization and to make this application on behalf of the organization. I certify that the information is correct and that the statements made herein, including all attachments and exhibits, are true and correct to the my knowledge. The submission of false information to the Massachusetts Life Sciences Center (MLSC) is subject to tion under the False Claims Law at M.G.L. c. 12, sections 5A – 5O.
Applicar	tand that this First Look Awards Program Application may be disqualified if it does not contain all required information or if the nt does not meet the eligibility criteria required under the Program. I also acknowledge and agree that the MLSC has sole on to determine which applicants receive benefits under the Program.
I specific	cally acknowledge that all of the terms and conditions of the Solicitation are mandatory.
within a applicabe the open of ended be proper Confider	alf of the applicant, I understand and acknowledge that all materials submitted as part of this application may be subject to re under the Massachusetts Public Records Law. "Public records" may not, however, include materials or data which fall specifically enumerated exemption set forth in the MLSC's enabling act, M.G.L. Chapter 23I. Such exemption may be ble to materials or data submitted to the MLSC that consist of trade secrets or commercial or financial information regarding ration of any business conducted by the company, or regarding the competitive position of such company in a particular field evor (Trade Secrets Exemption). I understand and acknowledge that if I wish to submit materials or data to the MLSC that may rietary in nature and may fall within the parameters of the Trade Secrets Exemption, I must identify such materials and data as intial. I also understand that the receipt of such materials/data by the MLSC does not represent a finding that such soldate do qualify for protection under the Trade Secrets Exemption.
How d	lid you hear about the program? (required)
O S	ocial Media
	ILSC Newsletter/Website
	hird Party (MassBio, MassMedic, etc.)
O 0	ther (specify below)
☐ Se	elect for the Principal Investigator to receive email notices and updates from the MLSC

You may unsubscribe at any time.

We look forward to reviewing your application and working together to advance research in women's health. If you have any questions or need assistance, please get in touch with our team at Form saved successfully. WomensHealth@masslifesciences.com with First Look Awards in the subject line.

Save Draft Submit Form

Drafts may be visible to the administrators of this program.